How to Add Sermorelin to a Medical Practice (2026)

Adding sermorelin to a medical practice requires a licensed prescriber, state-compliant clinical workflow, qualified pharmacy relationship and accurate consent materials. No FDA-approved sermorelin product is marketed in the United States today: the former product Geref had limited historical indications and its approval was withdrawn effective June 18, 2009. A compounded program therefore needs especially careful clinical and marketing controls.

Is sermorelin FDA approved?

No FDA-approved sermorelin product is marketed in the United States today. FDA records identify Geref, sermorelin acetate for injection, as previously approved for limited pediatric growth-hormone-deficiency-related use and as a diagnostic product. The approval was withdrawn effective June 18, 2009, and FDA records state that the product was no longer marketed in the United States.

That history matters when a founder is deciding how to describe a sermorelin therapy business. Historical approval of Geref does not make a current compounded preparation FDA-approved, and it does not support presenting sermorelin as an FDA-approved anti-aging, weight-loss, muscle-building, performance or general wellness product.

FDA has also warned a seller that marketing sermorelin for claims including metabolic improvement and fat loss involved an unapproved new drug. A practice should keep the discontinued product’s historical labeling separate from any current service description, clinical rationale or compounded medication workflow.

Compounded drugs are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness or quality in the same manner as approved drugs. That distinction belongs in internal training, website review, intake materials and informed consent.

What does a sermorelin program for clinics involve?

A clinic program is a coordinated medical service, not a vial added to a spa menu. The core components are clinical evaluation, prescribing authority, pharmacy sourcing, consent, follow-up, records and advertising review.

The owner can design the business workflow, but cannot turn a clinical protocol into a substitute for patient-specific judgment. MDLaunchr provides white-label telehealth infrastructure for branded programs; the platform runs the business operations while independently licensed clinicians make the clinical decisions. That division should be visible in agreements, workflows, staff training and patient communications.

How do I add sermorelin to my medical practice?

Use a staged review rather than launching from a product menu. The sequence below gives a practice owner a workable setup framework without prescribing a clinical regimen.

1. Define the service and its boundaries

Start by deciding what the practice is actually offering: a clinician-evaluated program that may involve compounded sermorelin when a prescriber determines it is appropriate. Do not begin with a promise about age reversal, body composition, energy, sleep, metabolism or performance.

The website should not call the service an FDA-approved anti-aging therapy, a clinically proven fat-loss treatment or guaranteed hormone optimization. It should explain that the service is medical, individualized and not appropriate for every patient.

2. Separate business control from medical control

Identify the clinical entity, administrative entity, prescribers and medical leadership before patient enrollment begins. The business may control branding, scheduling, customer support, technology and administrative processes. It should not control diagnosis, patient selection, prescribing criteria, clinical documentation, follow-up decisions or discontinuation.

The owner should have the proposed entity structure, clinician agreements and financial relationships reviewed once by qualified healthcare counsel or the applicable professional board before launch. Rules differ by state, ownership model and clinician license type.

3. Build the prescriber workflow

The prescriber should independently evaluate each patient, review relevant history and medications, consider risks and alternatives, determine whether telehealth is clinically adequate, and document the treatment decision. The workflow should also specify follow-up, monitoring, adverse-event management, referral and circumstances in which treatment may be declined or discontinued.

A health coach, marketer, pharmacy, protocol vendor or business owner should not make the prescribing decision. The practice should retain records showing who evaluated the patient and who authorized the prescription.

4. Confirm state licensure and telehealth rules

For telehealth, the clinician generally needs to be licensed or otherwise authorized where the patient is physically located, subject to that state’s requirements. There is no single national sermorelin telehealth rule.

In Texas, certain remote acts affecting the diagnosis or treatment of a patient in Texas are treated as the practice of medicine in Texas. Texas telemedicine rules also address establishing the physician-patient relationship, identifying the patient, making an appropriate diagnosis, discussing risks and benefits, and maintaining follow-up availability.

Florida takes a different approach to the telehealth modality. Florida materials state that a telehealth provider may conduct an evaluation sufficient to diagnose and treat without first researching medical history or performing a physical examination, while still remaining subject to scope-of-practice requirements and the professional standard applicable to in-person care. Florida also has registration and other conditions for certain out-of-state telehealth providers.

Massachusetts requires a physician practicing through a business organization to use an authorized organizational form or a qualifying healthcare-facility arrangement. A Massachusetts owner should separately review the proposed professional entity, administrative company and any clinic-level requirements.

These examples are not a national rule. A state-by-state review should address ownership, corporate-practice restrictions, supervision, prescriber scope, telehealth encounters, pharmacy shipment and office-stock rules.

5. Evaluate the pharmacy relationship

A clinic should not select a source simply because it supplies peptides or offers business pricing. Under the federal framework, a 503A pharmacy generally compounds for an identified individual patient pursuant to a valid prescription. A 503B outsourcing facility may compound without patient-specific prescriptions in circumstances allowed by law, but it remains subject to its own statutory and manufacturing requirements.

Before working with a pharmacy, verify:

• Whether it is a state-licensed 503A pharmacy or FDA-registered 503B outsourcing facility.
• Current licensure and registration status.
• Relevant FDA inspection, recall, warning-letter and enforcement history.
• Labeling, storage, shipping and beyond-use-date procedures.
• Lot tracking and documentation related to sterility or product quality.
• Whether it may lawfully dispense or ship into every target patient’s state.
• Written procedures for complaints, recalls, temperature excursions and adverse-event reports.

FDA enforcement records include recalls involving compounded sermorelin products and warning letters concerning online sellers that marketed sermorelin as an unapproved drug. Pharmacy diligence should therefore be part of launch approval, not a later procurement task.

6. Draft consent before advertising

Consent should explain the current FDA status of sermorelin, whether the proposed preparation is compounded, the proposed clinical rationale, known and reasonably foreseeable risks, limitations and uncertainties, alternatives including no treatment, pharmacy arrangements, follow-up and monitoring, adverse-event reporting, recall handling, and telehealth limitations when applicable.

The document should also make clear that a clinician may decline or discontinue treatment. It should not imply that FDA reviewed or endorsed the clinic’s compounded product, protocol, outcomes or marketing claims.

Consent is not a replacement for a clinical evaluation. It is one part of a documented process that helps the patient understand what the practice is offering and what remains uncertain.

7. Review every claim and creative asset

FTC guidance requires health-related advertising to be truthful, not misleading and supported by competent and reliable scientific evidence. This applies to express claims and implied claims conveyed through headlines, images, testimonials, endorsements and the overall context of an advertisement.

For a sermorelin program, create a claim file containing the exact website, social, email and intake language; evidence supporting each objective claim; publication dates and versions; testimonial disclosures; and approval records. Avoid claims such as “reverses aging,” “builds muscle,” “improves metabolism,” “clinically proven fat loss” or “guaranteed hormone optimization” unless the specific claim is adequately supported and legally permissible in context.

Testimonials do not automatically supply the scientific substantiation required for an objective health claim. A before-and-after image can also communicate an implied outcome even when the caption is carefully worded.

Can a med spa offer sermorelin?

A med spa may be able to offer a clinician-led sermorelin program, but the answer depends on state law, entity structure, prescriber authority, pharmacy rules and clinical standards. A spa owner cannot assume that ownership of a nonclinical business permits control over medical decisions.

In Texas, the Medical Board describes corporate-practice and physician-independence concerns that can restrict corporations, entities or nonphysicians from practicing medicine. Texas business policies may not compromise independent medical judgment. A nonphysician-owned Texas med spa should review employment, medical-director, management-services and protocol arrangements before launch.

In Florida, the permissive telehealth modality does not eliminate scope-of-practice or professional-standard obligations. In Massachusetts, the proposed professional organization and relationship with any administrative company require separate review under the state’s business-organization rules.

The same brand and intake funnel may serve several states, but the clinical and legal configuration may need to change by patient location.

What should a clinic say about sermorelin?

A defensible description identifies the service as a clinician-evaluated medical program that may involve a compounded medication, is subject to individualized medical judgment, is not an FDA-approved anti-aging or weight-loss product, is not appropriate for everyone, and includes follow-up rather than guaranteed outcomes.

That wording is educational rather than promotional. It also avoids implying that a compounded preparation is the same as, equivalent to or a generic version of a formerly marketed product. The practice should distinguish clearly between a historical FDA approval and the current status of a compounded preparation.

For broader planning, the white-label telehealth programs hub can help an owner compare how a branded clinical service fits into a larger platform strategy. MDLaunchr is one infrastructure option, not a regulator, pharmacy, law firm or treating clinician. Platform infrastructure can organize intake, branding, communications and operations, but it does not remove the owner’s responsibility to use an appropriate clinical and legal structure.

Sermorelin launch checklist for practice owners

Before publishing a program page or accepting an intake, verify each item:

• The historical FDA status and current compounded-drug status are stated accurately.
• The clinical entity and administrative entity are identified.
• Medical decisions remain with authorized clinicians.
• Each prescriber’s state license and scope are checked for the patient’s location.
• The telehealth workflow addresses evaluation, follow-up and emergency limitations.
• The pharmacy’s 503A or 503B status is documented.
• Shipping, labeling, storage, lot tracking and recall procedures are documented.
• Consent addresses uncertainty, alternatives, compounded status and pharmacy arrangements.
• Website, social, email and testimonial claims have evidence and approval records.
• Records cover evaluation, prescription, consent, follow-up, complaints and adverse events.
• Financial and referral arrangements have been reviewed for applicable restrictions.
• State-specific questions are resolved before expansion into another market.

If your business is evaluating a branded, clinician-led route, see the white-label sermorelin program to review how the program is set up.

Scope and disclaimer

This article is educational B2B content for practice owners and healthcare entrepreneurs. It is not medical advice, legal advice, pharmacy advice or a substitute for review by a licensed clinician, qualified healthcare attorney, pharmacy professional or applicable regulator. Federal and state rules can change, and the sources cited here should be checked before launch or expansion.

Related reading: Good Faith Exam by Telehealth for Med Spas: State Rules, Build vs. White-Label GLP-1 Telehealth: Which Model Fits?.